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Abstract: Epigenetic reprogramming plays a crucial role in the tumorigenicity and maintenance of tumor-specific gene expression that
especially occurs through DNA methylation and/or histone modifications. It has well-defined mechanisms. It is known that alterations
in the DNA methylation pattern and/or the loss of specific histone acetylation/methylation markers are related to several hallmarks of
cancer, such as drug resistance, stemness, epithelial–mesenchymal transition, and metastasis. It has also recently been highlighted that
epigenetic alterations are critical for the regulation of the stemlike properties of cancer cells (tumor-initiating cells; cancer stem cells).
Cancer stem cells are thought to be responsible for the recurrence of cancer which makes the patient return to the clinic with metastatic
tumor tissue. Hence, the dysregulation of epigenetic machinery represents potential new therapeutic targets. Therefore, compounds with
epigenetic activities have become crucial for developing new therapy regimens (e.g., antimetastatic agents) in the fight against cancer.
Here, we review the epigenetic modifiers that have already been used in the clinic and/or in clinical trials, related preclinical studies in
cancer therapy, and the smart combination strategies that target cancer stem cells along with the other cancer cells. The emerging role of
epitranscriptome (RNA epigenetic) in cancer therapy has also been included in this review as a new avenue and potential target for the
better management of cancer-beneficial epigenetic machinery.
Key words: Epigenetic modifications, RNA epigenetic, anticancer drugs, cancer stem cells

1. Introduction
Success in cancer treatment is still not satisfactory, although
new chemotherapeutics have recently been introduced in
the clinic. For a decade, it has been considered that the
most important reason for the poor success rate in cancer
therapy is the presence of cancer stem cells (CSCs) that
represent tumor heterogenicity. It has been shown that
CSCs are resistant to treatment and that they play a
crucial role in recurrence (Easwaran et al., 2014; Toh et
al., 2017). It is now known that classic genetics alone is
insufficient to explain the diversity of phenotypes within a
population. Therefore, new therapy regimes which include
epigenetic modifiers have begun assessment in clinical
trials (Samavat et al., 2016; Azad et al., 2017; Von Hoff et
al., 2018). Recent studies suggest differential alterations in
epigenetic mechanisms for several cancers such as breast,
colon, lung, prostate, and brain tumors (glioblastoma
multiforme) (Bachmann et al., 2006; Kagara et al., 2012;
Vedeld et al., 2014). It has been reported that genespecific hypermethylation of DNA and/or modulation of
the histone acetylation program are the most abundant
modifications of tumorigenesis that can be reversed by

the epigenetic modifiers (Fraga et al., 2005). Furthermore,
it has been shown that use of these modulators in
combination with conventional chemotherapeutics
exhibits chemo-prevention activity against different types
of cancer (Fang et al., 2010; Matei et al., 2012; Von Hoff
et al., 2018). There are also several preclinical studies that
have shown promising results in targeting CSCs via these
drugs (Tian et al., 2012; Liu et al., 2015; Jiang et al., 2018).
In addition, identification of the role of epitranscriptome
in cancer-related processes has become a new research
area due to its association with aggressive tumor character
(Zhang et al., 2017). There are a few studies regarding the
modulation of this process resulting in the elimination
of cancerous cells as well as CSCs, implying new possible
targets in this area (Zhang et al., 2016; Cui et al., 2017; Zhao
et al., 2017). Thus, the current review aims to address the
following questions: i) How does epigenetic machinery
contribute to tumor growth and progression? ii) What are
the current clinical and preclinical studies on the usage of
epigenetic modifiers in cancer therapy? iii) What are the
benefits of using these modifiers to target CSCs? iv) How
can combinatorial therapy be effectively used to target/
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inhibit these cells? v) What is the role of epitranscriptome
in cancer therapy?
2. Epigenetic mechanisms
The term epigenetics was first used by Conrad Waddington
in 1942 and is defined as all changes inherited through
the alteration of gene expression without alteration of the
DNA sequence (Herceg, 2007). Epigenetic gene regulation
occurs through covalent modifications of both DNA and
chromatin, and modulates gene transcription by opening
the chromatin structure (euchromatin, active gene
transcription) or by providing a condensed DNA construct
(heterochromatin, suppressed gene expression) (Meissner,
2010). DNA methylation and histone modifications are
two important epigenetic modifications included in several
biological processes such as embryonic development,
cellular memory, cell, and tissue-specific gene expression,
differentiation, and adult tissue maintenance (Meissner,
2010; Tammen et al., 2013). On the other hand, noncoding
RNAs such as piRNAs, miRNAs, and long noncoding
RNAs are also important epigenetic regulators discussed
in detail elsewhere, but they are not the focus of this review
(Wei et al., 2017).
2.1. DNA methylation
DNA methylation refers to the addition of a methyl
(CH3) group covalently to the cytosine bases of the CG
dinucleotides (CpG) at the fifth carbon position by the
DNA methyl transferases (DNMT), which changes cell
functions by altering gene expression (Bird, 2002). CpG
islands refer to the frequency of CG sequences, which is
higher than that of other regions in the genome in which
chromatin structure and gene expression are modulated
(Baylin, 2005). The promoters of transcriptionally active
genes (housekeeping genes and most regulatory genes)
are associated with this region and are unmethylated.
The methylation of cytosine in CpG islands is associated
with transcriptional silencing. It is hence a regulatory
mechanism for gene expression (Bird, 2002). Gene silencing
by DNA methylation occurs through the suppression of
transcription factors binding to the promoter region or
induction of binding proteins (MBD; methylated CpG
binding proteins) which are specific to these methylated
regions (Klose and Bird, 2006).
2.2. Histone modifications
DNA and histones are organized into nucleosomes to form
the chromatin structure in eukaryotes. Each nucleosome
core consists of a histone octamer containing a pair
of H2A, H2B, H3, and H4 histone proteins, and each
nucleosome is connected with the linker DNA. The linker
H1 histone binds to the entry and exit region of DNA on
the histone core (Annunziato, 2008). Each histone core
has a long N-terminal amino acid tail that extends from
the nucleosome structure, and these histone tails exhibit
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various posttranslational modifications that control the
chromatin structure, such as acetylation, methylation,
phosphorylation, ubiquitination. These specific histone
modifications on lysine (K), serine (S), and arginine
(R) residues are known as histone code and may be an
activator or a suppressor according to the specific region
modified. Modulation of histones are regulated by histone
acetyl transferases (HATs), histone methyltransferases
(HMTs), histone deacetylases (HDACs), and histone
demethylases (HDMs) through the addition or removal of
methyl or acetyl groups to/from the histone tails (Shi, 2007;
Haberland et al., 2009). Generally, acetylation provides
the euchromatin state through the charge neutralization
between DNA and histones, and is associated with
transcriptional activity. On the other hand, methylation
can activate or repress transcription depending on which
residue is modified (Bernstein et al., 2007; Bannister and
Kouzarides, 2011). For example, while the addition of 3
methyl groups to the 4th lysine residue of H3 histone
protein (H3K4me3) is an active mark, trimethylation of
the 27th lysine residue of H3 histone protein (H3K27me3)
is a repressive mark (Jenuwein and Allis, 2001).
Polycomb group (PcG) proteins are exclusive
chromatin-modifying transcriptional repressors that
determine the cell’s fate by regulation of pluripotency and/
or differentiation of cells. Modulation of histones by PcG
proteins provides the maintenance of pluripotency in early
embryonic development, and is also responsible for the
silencing of pluripotency genes following differentiation
(Bernstein et al., 2006). Enhancer of zeste homolog 2
(Ezh2) is a well-known PcG protein and an HMT catalyzing
trimethylation of lysine 27 of the H3 mark, and is essential
for the maintenance of embryonic stem cell pluripotency
(Vire et al., 2006).
3. Epigenetic status in cancer
The cancer genome is generally hypomethylated, which
causes increased genomic instability, as well as activation
of prosurvival and growth-promoting genes (Jones and
Baylin, 2007). On the other hand, it is known that there
is gene-specific hypermethylation in tumors resulting in
transcriptional inactivation of tumor suppressor genes
such as Rb, BRCA1, and MLH1 (Baylin, 2005; Jones
and Baylin, 2007). In addition to alterations in DNA,
modification of histones is also involved in the process of
tumorigenesis. Loss of acetylation at lysine 16 (H4K16ac,
active mark) and trimethylation at lysine 20 of histone
H4 (H4K20me3, repressive mark) have been indicated as
common hallmarks of various forms of cancer (Fraga et al.,
2005). HDACs are often found overexpressed in various
types of cancer and thus have become a major target of
epigenetic therapy (Halkidou et al., 2004; Noh et al., 2006;
Hayashi et al., 2010). Along with HDACs, deregulation of
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HMTs is related to tumor initiation and progression, and
is especially responsible for methylation at lysines 4, 9,
and 27 of histone H3 (Nguyen et al., 2002; Valk-Lingbeek
et al., 2004; Kondo et al., 2008). Elevated levels of Ezh2
protein have been reported in prostate and breast cancer
(Valk-Lingbeek et al., 2004). Furthermore, recent studies
have stated that Ezh2 overexpression is associated with
aggressiveness and progression of different cancer types
such as prostate, breast, bladder, and endometrial cancer,
as well as melanoma (Bachmann et al., 2006; Clermont et
al., 2017).
Research on epigenetic therapy which has especially
focused on DNMT and HDAC inhibitors as enlightened
epigenetic mechanisms in cancer accelerated in the
early 2000s. It has been shown that cancer-beneficial
epigenetic modifications are critical for tumor initiation
and progression because of these modifications related
to the hallmarks of cancer. Differential epigenetic
processing has been stated in normal cells, cancer cells,
and CSCs (Figure). Hence, research on epigenetic
therapy has gained momentum in recent years to target
these mechanisms. Newly discovered inhibitors have
been introduced in addition to DNMT and HDAC
inhibitors, such as bromodomain and extraterminal
protein (BET), histone methyltransferase (HMT), protein
arginine methyltransferase (PRMT), and lysine-specific
demethylase 1A (LSD1/KDM1A) inhibitors, which are
able to target different epigenetic mechanisms (Jones et al.,
2016). It has been shown in these studies that epigenetic
drugs (epidrugs) have promising results for the treatment
of cancer. Currently, there are 6 FDA-approved epigenetic
drugs used in oncology, and more than 50 epigenetic drug
candidates are being examined in preclinical and clinical
trials. Moreover, combinatorial usage of epidrugs is in
preclinical and/or clinical trials (Tables 1 and 2).
3.1. Targeting DNA modifications in cancer therapy
Among the most frequently studied DNA modifiers are
DNMT inhibitors that are modified forms of cytosine and
act as cytosine analogs. Currently, two of them, azacytidine
and decitabine, are approved by the FDA for clinical usage
(Verma and Kumar, 2018). Their mechanism of action is
that decitabine incorporates into DNA whereas azacytidine
incorporates into both RNA and DNA; both then lead to
degradation of DNA methyltransferases (Toh et al., 2017).
They were first developed as cytotoxic agents against
cancer in 1964. Subsequent studies have shown that lowdose azacytidine or decitabine inhibits DNA methylation
(Christman, 2002). In 2004 and 2006 respectively, the
FDA approved azacytidine and decitabine following
reassuring results on the treatment of myelodysplastic
syndrome (MDS), which is considered preleukemia (Sato
et al., 2017). Furthermore, both azacytidine and decitabine
have shown promising results on AML and CML because

they delay the time to AML transformation from MDS
or death (Kornblith et al., 2002; Kantarjian et al., 2006).
There have been 13 completed Phase 3 clinical trials on
azacytidine treatment in leukemia and MDS. However,
because of the serious side effects observed in these
studies, new interventions are being tried in 9 active trials.
There are over 200 clinical trials in different phases on
different type of cancers with azacytidine and decitabine.
Matei et al. (2012) showed in a Phase 2 study that lowdose decitabine affects the gene methylation of cancerrelated pathways, restores sensitivity to carboplatin, and
increases response rate and progression-free survival
(PFS) in ovarian cancer patients (Matei et al., 2012).
Another phase study reported that a low-dose decitabine
and carboplatin combination is well tolerated, and resulted
in DNA hypomethylation in patients with ovarian cancer
(Fang et al., 2010). Phase 1/2 studies using combinatorial
therapy with azacytidine and valproic acid or entinostat
showed that tumor-associated methylated genes were
demethylated. However, some side effects occurred, such
as neutropenic fever, thrombocytopenia, and anemia
(Braiteh et al., 2008; Juergens et al., 2011). Sequential
administration of azacytidine and lenalidomide, but not
in high doses, has shown clinical activity in patients 60
years or older with AML (Medeiros et al., 2018). CC-486,
an oral formulation of azacytidine, has resulted in partial
response and stable disease in nasopharyngeal cancer
patients. The same Phase 1 study showed that CC-486
alone or in combination with carboplatin or nab-paclitaxel
(nanoparticle albumin-bound) are well tolerated and no
drug–drug interactions were detected (Von Hoff et al.,
2018). The immunomodulatory effect of azacytidine was
identified in breast, colon, and ovarian cancer cells in
vitro with alteration of immune gene methylation (Li et
al., 2014). This data suggests that usage of azacytidine in
combination with immunotherapy may be an option for
cancer treatment.
Small molecule inhibitors have been developed that
inhibit DNA methylation without being incorporated into
DNA (Brueckner et al., 2005). SGI-110 (guadecitabine),
the prodrug form of decitabine, is a small molecule of DNA
methylation inhibitor. SGI-110 has been used to increase
chemosensitivity in colon cancer and ovarian cancer with
combinatorial therapies in vitro and in vivo (Fang et al.,
2014). There are clinical trials on SGI-110 in Phases 2
and 3 on different types of solid cancers, but results have
not been published yet. On the other hand, SGI-110 has
immunomodulatory activity similar to that of azacytidine
(Li et al., 2014; Srivastava et al., 2015). Hence, combination
therapy of DNA modifiers with immunotherapy may
produce promising results for cancer treatment.
Additionally, there are several natural compounds that
affect DNMTs. One of these compounds is epigallocatechin
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Figure. Overview of the hot top epigenetic alterations in normal cells, cancer, and CSCs.
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Phase 3

Phase 2

VPA





Clinically useful in low-risk MDS

Increased PFS

 A set of genes is associated with
Kuendgen et al., 2005
clinical response
Raffoux et al., 2010
 Encouraging findings for improved
Krauze et al., 2015
outcomes
+ ATRA and 5-Azacytidine
+ Standard radiation therapy
and temozolomide

San-Miguel et al., 2014
Richardson et al., 2016
San-Miguel et al., 2016


+Bortezomib and
Dexamethasone (Phase 3)

The overall survival benefit

Thomas et al., 2014
O’Connor et al., 2015
 Combination is active without
additive toxicities

Panobinostat

 Complete and durable responses
with manageable toxicity

+ Cisplatin, Doxorubicin, and
Cyclophosphamide (Phase 1/2)

Phase 2

Limited activity alone

Haigentz et al., 2012
Gerber et al. 2015

Belinostat



 Encouraging findings for disease
control

Romidepsin

+ Erlotinib (Phase 1)

Phase 3

SAHA

Luu et al., 2008
Modesitt et al., 2008
Traynor et al., 2009
Burke et al., 2014
 Reported encouraging results to
reverse chemotherapy resistance in
relapsed/refractory ALL

 No objective antitumor activity
Phase 1/2  No complete or partial responses
but
stable disease

Samavat et al., 2016

+Decitabine by the following
chemotherapy: Vincristine,
Dexamethasone, Mitoxantrone
(Phase 1/2)

Phase 2

EPG

 Increased sensitivity to carboplatin Kantarjian et al., 2006
Fang et al., 2010
 Decrement in global DNA
Matei et al., 2012
methylation
N/A

Phase 2
Phase 3

Decitabine

References

Kornblith et al., 2002
 Increased median PFS and overall
Braiteh et al., 2008
survival.
Juergens et al., 2011
 Demethylation of tumor associated
Azad et al., 2017
genes.
Von Hoff et al., 2018

Effect/limitation
(combined)

N/A

+Carboplatin (Phase 1)

 Increased PFS
 Delayed transformation from
MDS to AML
 Toxicity: nausea, allergic reactions,
neutropenia, fatigue

Phase 1
Phase 3

Azacytidine

Decrement in circulating tumor cells

+Entinostat (Phase 1/2)
+VPA (Phase 1/2)

 Delayed transformation from
MDS to AML
 Serious side effects.
 Resulted with partial response and
stable disease (CC-486).



Combinatorial therapy

Effect/limitation
(alone)

Status

Epigenetic drug

Table 1. Epigenetic modifiers used in clinic trials.
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+Nutlin-3
+SAHA
+Carboplatin
+Cisplatin
+Rapamycin

+5-FU

+Folfox

Decrement in global H3K27me3
Inhibition of proliferation and migration

Anticancer activity

Inhibition of angiogenesis
Inhibition of PD-L1 expression

Inhibition of tumor progression and metastasis
Reduced circulating tumor cells
Decreased stemness

Decreased CpG methylation of DLEC1
Inhibited anchorage-independent growth
















DZNep

Decitabine

JQ1

EPG

Curcumin

Increased sensitivity to carboplatin and cisplatin
Increased global DNA hypomethylation

Induced apoptosis

Overcame gefitinib resistance

Increased sensitivity to paclitaxel
Overcame cisplatin resistance

Increased apoptosis

Synergistic effect





Enhanced chemotherapy induced apoptosis

Enhanced chemosensitivity

 Effective chemotherapeutic option for
osteosarcoma treatment



+Gefitinib

Decreased proliferation and increased cell death
Decreased tumorigenesis




Panobinostat



Induction of differentiation and apoptosis

VPA

Inhibition of proliferation and metastasis

+Cisplatin
+Etoposide



Belinostat

Antigrowth activity






Romidepsin

Cytotoxic activity
Relatively low toxicity against normal cells

+Paclitaxel
+Cisplatin



SAHA

 Increased sensitivity to anticancer agents and
apoptosis
 Overcome EGFR TKI resistance and increased
apoptosis
 Increased apoptotic and autophagic cell death

+Doxorubicine
+Cisplatin
+Bortezomib
+Tyrosine kinase
inhibitors (TKIs)
+Olaparib

Chemosensitizer
Overcame cisplatin resistance




+Oxaliplatin
+Cisplatin

Immunomodulatory effect






SGI-110

Increased chemosensitivity



Effect/limitation
(combined)

+CYC202



Azacytidine

Combinatorial
therapy
+ Temozolomide
+ Doxorubicin

Antigrowth activity
Immunomodulatory effect

Effect/limitation
(alone)




Epigenetic
drug

Table 2. Epigenetic modifiers used in preclinical studies.
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gallate (EPG), which has exhibited promising results in
Phases 2 and 3 clinical trials completed on skin, prostate,
breast, and colon cancers. One of the studies showed that
EPG containing green tea extract significantly reduced
circulating tumor cells in breast cancer patients (Samavat
et al., 2016). Kim et al. (2014) showed that EPG inhibits
progression of prostate cancer and metastasis in TRAMP
mice (Kim et al., 2014). Another natural compound that
affects DNA methylation is curcumin (Liu et al., 2009).
It has one clinical trial that is recruiting for prostate
cancer in Phase 3, as well as ongoing studies in Phase 2
against various type of cancers such as breast, pancreatic,
endometrial, prostate, and colorectal cancers. It has been
shown in vitro that curcumin reduces CpG methylation
of tumor suppressor DLEC1 gene promoter and inhibits
anchorage-independent growth in HT29 human colorectal
cancer cells (Guo et al., 2015).
There are several challenges for the usage of epigenetic
drugs alone in the treatment of solid tumors. One of the
limitations for DNMT inhibitors is the ability to provide
the penetration of the drug into tumor tissue and targeting
cancer cells. Furthermore, epidrugs affect multiple
pathways because they are not selective; they target global
epigenetic modifications. Another limitation is that they
work on actively dividing cells (Issa and Kantarjian, 2009).
Therefore, there are plenty of combinatorial therapies
with DNMT inhibitors and other epigenetic drugs,
conventional chemotherapy, or inhibitors. Azacytidine in
combination with entinostat, a class I HDAC inhibitor, has
been studied in treating 46 patients from 2 cohorts with
metastatic colorectal cancer in a Phase 2 trial. The median
PFS was stated as 1.9 months and overall survival was
stated as 5.6 months in cohort 1 and 8.3 months in cohort
2 (Azad et al., 2017). Decitabine and carboplatin have been
tested in platinum-resistant ovarian cancer patients; it was
found that low-dose decitabine affects cancer-related DNA
methylation and restores sensitivity to carboplatin (Fang
et al., 2010; Matei et al., 2012).
3.2. Targeting histone modifications in cancer therapy
It is known that HDACs are overexpressed in various
cancer types (Halkidou et al., 2004; Zhu et al., 2004;
Zhang et al., 2005; Noh et al., 2006). Therefore, targeting
HDACs has been considered an important strategy in
cancer treatment. The 5 currently FDA-approved HDAC
inhibitors are vorinostat (SAHA) for cutaneous T-cell
lymphoma, romidepsin for cutaneous/peripheral T-cell
lymphoma, belinostat for peripheral T-cell lymphoma,
panobinostat for multiple myeloma, and valproic acid
(VPA) for epilepsy, bipolar disorder, and migraine
(Eckschlager et al., 2017; Verma and Kumar, 2018).
There have been 5 completed Phase 3 clinical trials with
SAHA on lung cancer, glioma, multiple myeloma, and
leukemia, but results have not been posted yet. It has been

reported that SAHA did not exhibit antitumor activity
against head and neck cancers, breast, ovarian, colorectal,
and nonsmall cell lung cancers in Phase 2 clinical trials
(Blumenschein et al., 2008; Luu et al., 2008; Modesitt et al.,
2008; Vansteenkiste et al., 2008; Traynor et al., 2009). On
the other hand, combinatorial therapies with SAHA have
promising results in preclinical studies. Combinatorial
therapy with SAHA and olaparib, a PARP inhibitor
synergistically inhibited growth of triple negative breast
cancer cells, caused DNA damage and increased apoptotic
and autophagic cell death in vitro and in vivo (Min et al.,
2015). Another study showed that a combination of SAHA
and tyrosine kinase inhibitors (afatinib and WZ4002, third
generation of TKIs) overcame EGFR TKI resistance in
lung cancer cells and decreased cell viability both in vivo
and in vitro (Lee et al., 2015b). It has also been reported
that pretreatment with SAHA increases the cytotoxicity
of chemotherapy, even in chemo-resistant cells (Kim
et al., 2003). SAHA in combination with bortezomib, a
proteosome inhibitor, exhibited a synergistic and potential
effect in multiple myeloma, pancreatic cancer, and nude
mice xenografts (Nawrocki et al., 2006). Vijayaraghavalu
et al. (2012) demonstrated that treatment with decitabine
or SAHA sensitized chemoresistant MCF-7 breast cancer
cells to doxorubicin treatment. It has been shown that
belinostat inhibited growth of prostate cancer cells in
vitro, and reduced metastasis in vivo (Qian et al., 2008).
Another study showed that belinostat and a CDK inhibitor
(CYC202) significantly reduced proliferation and increased
apoptosis via upregulating p53 and BID activation (Ong et
al., 2016).
Romidepsin, a cyclicpeptide HDAC inhibitor and
natural product isolated from a bacterium, has been tested
in a completed Phase 3 trial in 27 countries, including
Turkey (Falkenberg and Johnstone, 2014). Results indicate
that only 17% of patients showed a complete response and
17% of patients showed a partial response to romidepsin
(O’Connor et al., 2015). There is an active study with
romidepsin in Phase 3 against peripheral T-cell lymphoma.
The aim of the study is to compare the efficacy of romidepsin
when administered with CHOP (cyclophosphamide,
doxorubicin, vincristine, and prednisone) versus CHOP
alone in patients previously untreated for peripheral T-cell
lymphoma. The effect of romidepsin on solid tumors has
been studied in 21 completed Phase 2 trials. One of these
studies was on radioactive iodine used on irresponsive
recurrent and metastatic thyroid cancer; it was reported
that “no RECIST (Response Evaluation Criteria in Solid
Tumors) major responses have been seen” (Sherman
et al., 2013). In another study, no objective response to
romidepsin was observed in patients with recurrent/
metastatic head and neck cancer, as romidepsin alone
has limited activity in treating squamous cell carcinoma
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of the head and neck (Haigentz Jr et al., 2012). Therefore,
combinatorial therapies are considered important. It has
been reported that the combination of romidepsin and
cisplatin or etoposide exhibits a synergistic effect on lung
cancer cells in vitro (Luchenko et al., 2011).
VPA is a member of the short-chain fatty acid HDAC
inhibitor class and is known to be a weak inhibitor of
HDAC. However, a case report has been published about
the combinatorial usage of valproic acid, cisplatin, and
doxorubicin in addition to radiotherapy and surgery
to successfully treat a patient with thyroid carcinoma
(Noguchi et al., 2008). Currently, VPA is being studied
in breast cancer and glial cell tumor in two Phase 2
trials. Furthermore, VPA has shown promising results in
neuroblastoma, bladder cancer, thyroid cancer, and breast
cancer. VPA induces differentiation and apoptosis through
activating Notch signaling in human neuroblastoma cells,
reduces proliferation and invasion in bladder cancer cells,
increases sensitivity to paclitaxel in thyroid cancer cells,
circumvents hypoxia-induced resistance to CDDP-induced
apoptosis in neuroblastoma cells, and increases histone H3
acetylation and apoptosis in breast CSCs (Stockhausen et
al., 2005; Chen et al., 2006; Catalano et al., 2007; Cipro
et al., 2012; Aztopal et al., 2018b). Furthermore, it has
been reported that VPA induces apoptosis and sensitizes
melanoma cells to cisplatin and etoposide treatment
(Valentini et al., 2007).
Another FDA-approved HDAC inhibitor, panobinostat,
increased PFS and showed a better benefit:risk profile
in patients with relapsed or relapsed and refractory
multiple myeloma in Phase 3 studies (San-Miguel et al.,
2014; Richardson et al., 2016). It has been reported that
panobinostat decreased proliferation, increased the
expression of tumor suppressor genes in triple negative
breast cancer cells, and decreased tumorogenesis in vivo
(Tate et al., 2012). Another study showed that panobinostat
overcame gefitinib resistance in KRAS-mutant nonsmall
cell lung cancer through the downregulation of TAZ (Lee
et al., 2017).
The 3-deazaneplanocin A (DZNep), a small molecule
inhibitor of Ezh2, decreases global H3K27 trimethylation,
and its overexpression is associated with aggressiveness
of several cancers such as prostate, breast, and bladder, as
well as melanoma (Bachmann et al., 2006; Clermont et al.,
2017). It has been shown that DZNep causes inhibition of
proliferation and migration in mesothelioma (Kemp et al.,
2012). Combinatorial therapy with DZNep and nutlin-3
inhibits the interaction between mdm2 and p53-induced
apoptosis in HCT116 colon cancer cells through the
reduction of bcl-2 expression (Zhou et al., 2018). When
DZNep was combined with another HDAC inhibitor
SAHA, it induced apoptosis in nonsmall cell lung cancer
through the EGFR pathway in vitro and in vivo (Takashina
et al., 2016).
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Another strategy in epigenetic therapy is targeting
BET bromodomain proteins. Bromodomains (BRDs)
are “readers” of acetyl marks in histone tails, targeting
chromatin-modifying enzymes and other protein
machinery to specific sites in the chromatin, thus
regulating gene transcription (Pérez-Salvia and Esteller,
2017). JQ1 and IBET762 are 2 well-known selective BET
inhibitors (Filippakopoulos et al., 2010). Studies showed
that JQ1 blocked binding of the androgen receptor (AR) to
the target gene by disrupting BRD4 and AR interaction in
castration-resistant prostate cancer (Asangani et al., 2014).
JQ1 and IBET762 suppressed proliferation in pancreatic
cancer cells as well as inhibited production of nitric oxide
and inflammatory cytokines, which are important for the
tumor microenvironment in pancreatic cancer cells and
immune cells (Leal et al., 2017). PD-L1 expression was
inhibited by JQ1 in both immune cells and ovarian tumors
in vivo (Zhu et al. 2016). Da Motta et al. (2017) showed
that JQ1 negatively affects tumor response to hypoxia and
angiogenesis (da Motta et al., 2017). However, there has
been no report regarding the usage of JQ1 in phase trials.
On the other hand, there are 6 ongoing phase trials with
IBET762 in cancer treatment, especially in solid tumors.
All of these studies suggest that when epigenetic drugs
are used alone, they have promising results in vitro. On
the other hand, combinatorial usage of these drugs with
chemotherapy seems more effective in the clinic. It is
known that conventional chemotherapeutics target the
DNA of rapidly dividing cells. Epidrugs make DNA more
targetable for these agents by releasing DNA from the
nucleosome and/or allowing the binding of transcription
factors to the promoter of specific genes that trigger
active gene expression, such as tumor suppressor genes.
Furthermore, epidrugs may be more effective in clinical
studies due to their immunomodulatory effects, which are
necessary for immune cells to target cancer cells.
4. Epigenetic status in cancer stem cells
CSCs are a subset of tumor cells which are considered the
most important reason for the poor success rate in cancer
therapy. Recent studies have revealed that epigenetic
alterations in these cells play a key role in the regulation
of stemness-related features. It has been shown that
differential expression of CD133, a well-known stemness
marker, is regulated by epigenetic modifications in many
cancer types. The CD133+ population is identified by the
promoter hypomethylation in several cancers such as
ovarian, glioblastoma, and colorectal when compared to
the CD133- population (Tabu et al., 2008; Yi et al., 2008;
Baba et al., 2009). It has been demonstrated that TGF-β
regulates the CD133 expression through the inhibition
of DNMT1 and DNMT3b in the hepatocellular cancer
cell line (You et al., 2010). Kagara et al. (2012) reported
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that hypomethylation of CD44, CD133, and Mushasi-1
promoters is associated with the overexpression of these
CSC markers in triple-negative breast tumors (Kagara et
al., 2012). DCLK1 (doublecortin-like kinase 1), a CSC
marker for intestinal and adenoma cancer, has been
recently identified as an epigenetic biomarker of colorectal
cancer which is regulated by promoter methylation (Vedeld
et al., 2014). Furthermore, CSCs isolated from breast and
pancreatic cancer cell lines exhibit higher expression
of Ezh2 as compared to the non-CSC populations.
Researchers have indicated that RNAi-mediated Ezh2
knockdown leads to decreased frequency of CSCs in these
cells, confirming the role of Ezh2 in the maintenance of
the CSC phenotype (van Vlerken et al., 2013). CDCP1
(CUB-domain containing protein 1) is a stem cell marker
which has been shown to be regulated by epigenetic
mechanisms in breast cancer cell lines as well as in clinical
findings (Ikeda et al., 2006). Reduction of CDCP1 is
associated with tumor invasiveness and poor prognosis
in esophageal cancer (Sawada et al., 2014). These results
suggest that dynamism in DNA methylation as well as
histone modifications contribute to tumor heterogeneity
through the transition between the active and repressive
state of stemness-related genes and represent a potential
target for epigenetic therapy.
4.1. Targeting DNA modifications in CSC therapy
It has been mentioned above that DNMT inhibitors
are highly toxic as cytotoxic agents, but in low doses
they have great efficacy in maintaining reduced DNA
methylation and reexpression of silenced genes in
leukemic and epithelial tumor cells (Tsai et al., 2012). It
has been predicted that they may reduce tumor formation
in cancer patients and target CSC populations within
the tumor. Liu et al. (2015) demonstrated that regulated
inhibition of DNMT1 was able to reduce the proliferation
and tumorigenic ability of lung CSCs (Liu et al., 2015). It
has been reported that decitabine-treated prostate cancer
CSCs exhibited diminished expression in stemness genes
OCT4 and Nanog, leading to a general decrease in tumor
growth (Tian et al., 2012). SGI-110, a novel DNMT
inhibitor, has been reported to reprogram ovarian CSCs to
a more differentiated state (Wang et al., 2014). It has been
reported that EPG induced apoptosis in lung CSCs through
hsa-mir-485-5p upregulation and RXRα downregulation,
which are CSC markers (Jiang et al., 2018). Chen et al.
(2017) reported that EPG showed an antiproliferative
effect, induced apoptosis, and reduced stem cell properties
by inhibiting the Wnt pathway in colorectal CSCs (Chen
et al., 2017). It has been stated that EPG inhibits STAT3
activation; hence, STAT3 target genes related to stemness
characterization in breast CSCs are downregulated (Chung
et al., 2015). Toden et al. (2016) demonstrated that EPG
induced apoptosis, caused cell cycle arrest, and diminished
CSC formation in colorectal CSCs (Toden et al., 2016).

4.2. Targeting histone modifications in CSC therapy
Therapy resistance is an important issue to overcome in
cancer treatment. This resistance is mostly associated with
CSCs and epigenetic regulation (Sharma et al., 2010).
SAHA and romidepsin are HDAC inhibitors that have been
approved for treatment of cutaneous T-cell lymphoma.
Both drugs were found to exhibit durable response and
efficacy in patients with cutaneous T-cell lymphoma
(Olsen et al., 2007; Piekarz et al., 2009; Whittaker et al.,
2010; Thaler et al., 2012). It has been reported in our
previous study that VPA negatively regulated self-renewal
capacity and induced caspase-independent apoptosis in
breast CSCs (Aztopal et al., 2018b). Higher activity of Ezh2
has been reported in different cancers such as breast, lung,
and prostate, as well as hematological malignancies, and is
associated with poor disease prognosis (Kleer et al., 2003;
Weikert et al., 2005; Simon and Lange, 2008; Li et al., 2013;
Wang et al., 2016). Further studies have also suggested the
role of Ezh2 deregulation in tumor progression, metastasis,
and maintenance of CSCs’ self-renewal properties
(Bracken et al., 2006; Suva et al., 2009; Shi et al., 2013).
Furthermore, it has been reported that inhibition of Ezh2
by DZNep was able to reduce self-renewal and tumorinitiating features of glioblastoma multiforme CSCs in
vivo through the transcriptional regulation of oncogene
MYC (Suva et al., 2009).
4.3. Combination therapy with epigenetic modulators in
CSC therapy
It has been highlighted in several recent studies that the
use of epigenetic drugs in combination with conventional
chemotherapy agents resensitizes resistant CSCs to drug
treatment, or primes cancer cells for subsequent therapies
(Easwaran et al., 2014; Juo et al., 2015). For instance, low
doses of SGI-110 (DNMT inhibitor) was established
to impel ovarian CSCs toward a more differentiated
phenotype and sensitize them to platinum treatment (Wang
et al., 2014). Li et al. (2015) reported that encapsulating
decitabine and doxorubicin in nanoparticles helped to
better target breast CSCs and inhibit tumor growth (Li et
al., 2015). In a recent study, coinhibition of Wnt, HDAC,
and Erα (estrogen receptor alpha) has been shown to
effectively suppress the breast CSC population. When
tamoxifen was added to this combination, it was reported
that the CSC population was successfully suppressed at
lower doses (Sulaiman et al., 2016). Chikamatsu et al.
(2013) showed that HDAC inhibition in head and neck
cancer exhibited a synergistic effect with chemotherapeutic
agents, suppressed stem cell character and EMT, stopped
the cell cycle, and induced apoptosis (Chikamatsu et al.
2013). It has been reported that EPG sensitized colorectal
cancer cells to 5-FU (Toden et al., 2016). Recently, our
research group demonstrated that the combination of VPA
with niclosamide (Wnt/β-catenin signaling inhibitor)
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increased histone H3 acetylation and induced extrinsic
apoptosis in breast CSCs in vitro (Aztopal et al., 2018a).
5. Emerging role of epitranscriptome in cancer therapy
Epitranscriptome refers to the posttranscriptional
regulation of gene expression via chemical RNA
modifications that do not change the RNA sequence
(Saletore et al., 2012). RNA modifications have begun
to be appreciated as emerging players in the regulation
of various biological processes, such as the maintenance
and differentiation of embryonic stem cells, modulation
of circadian rhythm, and stress response, as well as
tumorigenesis (Fustin et al., 2013; Geula et al., 2015;
Popis et al., 2016; Zhang et al., 2017). Although more than
150 RNA modifications are defined, the physiological
significance of only a few is known, especially in
tumorigenesis. Furthermore, it has been shown that these
modifications are dynamic and reversible like epigenetic
alterations, implying that their biological significance
in cancer therapy is comparable with DNA and histone
modifications (Zhao et al., 2017). Hence, RNA epigenetics
has become an attractive research area due to the discovery
of their targetable features in cancer therapy.
N6-methyladenosine (m6A) is the most common
modification in eukaryotic mRNAs and is well-studied
in cancer research (Desrosiers et al., 1974). Recent
accumulating evidence suggests that it has been a key
player in cancer-related hallmarks including cancer
stemness, EMT (epithelial–mesenchymal transition),
and drug resistance. Zhang et al. (2016) reported that
activation of ALKBH5 that demethylates m6A promotes

the stemness of breast CSCs (Zhang et al., 2016). Similarly,
it has been demonstrated that knockdown of METTL3
and METTL14 which catalyzes the formation of m6A
modification triggers the growth and self-renewal of
glioblastoma stem cells (Cui et al., 2017). Li et al. (2017)
showed that upregulation of METTL3 inhibits invasion and
migration capacity as well as EMT in renal cell carcinoma
in vitro and suppresses tumor growth in vivo (Li et al.,
2017). Moreover, it has been stated that overexpression
of YTHDF1 (m6A binding protein, reader) in colorectal
cancer is associated with poorer overall survival, and
that knockdown of YTHDF1 in vitro sensitizes cells to
anticancer drugs (Nishizawa et al., 2018). Overall, these
results suggest that manipulation of m6A levels modulates
aggressive tumor character and drug response, implying
its eligibility as a therapeutic target in drug discovery.
Conclusion
In conclusion, as given above, the potential of
epigenetic drugs in terms of their activity against solid
tumors is huge. Although there have been some failures
of epigenetic therapy on cancer, it is still of immense
importance and shows great promise for better outcomes
for cancer patients. Possibly the future discovery of various
small molecules which target the epigenetic regulators
might result in novel therapy modalities with more
specific actions. As given in detail above, the combination
of epigenetic agents with classical chemotherapy agents
and/or immunotherapy is a developing and especially
promising option for cancer patients which will surely
make a great impact on cancer treatment in the near future.
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